Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
07 11월 2023 - 7:15AM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, announced that on November 1, 2023, the Compensation
Committee of Puma’s Board of Directors approved the grant of an
inducement restricted stock unit award covering 15,000 shares of
Puma common stock to one new non-executive employee.
The award was granted under Puma’s 2017 Employment Inducement
Incentive Award Plan, which was adopted on April 27, 2017 and
provides for the granting of equity awards to new employees of
Puma. The
restricted stock unit award vests over a three-year period, with
one-third of the shares underlying the award vesting on the first
anniversary of the award’s vesting commencement date, November 1,
2023, and one-sixth of the shares underlying the award vesting on
each six-month anniversary of the vesting commencement date
thereafter, subject to continued service. The award was granted as
an inducement material to the new employee entering into employment
with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a
focus on the development and commercialization of innovative
products to enhance cancer care. Puma in-licensed the global
development and commercialization rights to PB272 (neratinib,
oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral
was approved by the U.S. Food and Drug Administration in 2017 for
the extended adjuvant treatment of adult patients with early stage
HER2-overexpressed/amplified breast cancer, following adjuvant
trastuzumab-based therapy, and is marketed in the United States as
NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also
approved by the FDA in combination with capecitabine for the
treatment of adult patients with advanced or metastatic
HER2-positive breast cancer who have received two or more prior
anti-HER2-based regimens in the metastatic setting. NERLYNX was
granted marketing authorization by the European Commission in 2018
for the extended adjuvant treatment of adult patients with early
stage hormone receptor-positive HER2-overexpressed/amplified breast
cancer and who are less than one year from completion of prior
adjuvant trastuzumab-based therapy. NERLYNX is a registered
trademark of Puma Biotechnology, Inc.
In September 2022, Puma entered into an exclusive license
agreement for the development and commercialization of the
anti-cancer drug alisertib, a selective, small molecule, orally
administered inhibitor of aurora kinase A. Initially, Puma intends
to focus the development of alisertib on the treatment of small
cell lung cancer and breast cancer.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106102522/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc.,
+1 424 248 6500 info@pumabiotechnology.com
ir@pumabiotechnology.com
Puma Biotechnology (NASDAQ:PBYI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Puma Biotechnology (NASDAQ:PBYI)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024